Top-Rated StocksTop-RatedNASDAQ:DYN Dyne Therapeutics (DYN) Stock Price, News & Analysis $34.73 -0.67 (-1.89%) (As of 10/17/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Dyne Therapeutics Stock (NASDAQ:DYN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Dyne Therapeutics alerts:Sign Up Key Stats Today's Range$34.71▼$35.7750-Day Range$31.68▼$47.0452-Week Range$6.40▼$47.45Volume669,647 shsAverage Volume1.54 million shsMarket Capitalization$3.03 billionP/E RatioN/ADividend YieldN/APrice Target$51.40Consensus RatingBuy Company OverviewDyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.Read More… [Urgent] Starlink Set For The Largest IPO In History? (Ad)He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000! And now, Elon could be set to do it for the third and final time… with what might be his biggest breakthrough yet. And for the first time ever, you have the rare chance to profit BEFORE the upcoming IPO.Click here now for the urgent details on this hidden play. Dyne Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks71st Percentile Overall ScoreDYN MarketRank™: Dyne Therapeutics scored higher than 71% of companies evaluated by MarketBeat, and ranked 339th out of 1,012 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.6 / 5Analyst RatingBuy Consensus RatingDyne Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.10, and is based on 9 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageDyne Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Dyne Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Dyne Therapeutics are expected to decrease in the coming year, from ($2.96) to ($3.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Dyne Therapeutics is -9.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Dyne Therapeutics is -9.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDyne Therapeutics has a P/B Ratio of 23.31. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Dyne Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.16% of the outstanding shares of Dyne Therapeutics have been sold short.Short Interest Ratio / Days to CoverDyne Therapeutics has a short interest ratio ("days to cover") of 6.9.Change versus previous monthShort interest in Dyne Therapeutics has recently increased by 15.93%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDyne Therapeutics does not currently pay a dividend.Dividend GrowthDyne Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted10.16% of the outstanding shares of Dyne Therapeutics have been sold short.Short Interest Ratio / Days to CoverDyne Therapeutics has a short interest ratio ("days to cover") of 6.9.Change versus previous monthShort interest in Dyne Therapeutics has recently increased by 15.93%, indicating that investor sentiment is decreasing significantly. News and Social Media1.8 / 5News Sentiment0.28 News SentimentDyne Therapeutics has a news sentiment score of 0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Dyne Therapeutics this week, compared to 6 articles on an average week.Search InterestOnly 3 people have searched for DYN on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Dyne Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership5.0 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Dyne Therapeutics insiders have sold 359.39% more of their company's stock than they have bought. Specifically, they have bought $1,057,280.00 in company stock and sold $4,857,019.00 in company stock.Percentage Held by Insiders20.77% of the stock of Dyne Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.68% of the stock of Dyne Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Dyne Therapeutics' insider trading history. Receive DYN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dyne Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address DYN Stock News HeadlinesDyne Therapeutics, Inc. (NASDAQ:DYN) Director Sells $82,636.42 in StockSeptember 28, 2024 | insidertrades.comDirk Kersten Sells 40,831 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) StockSeptember 25, 2024 | insidertrades.com[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000! And now, Elon could be set to do it for the third and final time… with what might be his biggest breakthrough yet. And for the first time ever, you have the rare chance to profit BEFORE the upcoming IPO.October 17, 2024 | Paradigm Press (Ad)Dyne Therapeutics, Inc. (NASDAQ:DYN) SVP Sells $48,024.50 in StockSeptember 20, 2024 | insidertrades.comDyne Therapeutics, Inc. (NASDAQ:DYN) COO Susanna Gatti High Sells 8,976 SharesSeptember 20, 2024 | insidertrades.comDyne Therapeutics, Inc. (NASDAQ:DYN) Receives Average Recommendation of "Buy" from AnalystsOctober 16 at 2:17 AM | americanbankingnews.comSarepta Therapeutics (NASDAQ:SRPT) Stock Quotes, Forecast and News SummaryOctober 14 at 6:25 AM | benzinga.comOctagon Capital Advisors LP Increases Stake in ArriVent BioPharma IncOctober 12, 2024 | finance.yahoo.comSee More Headlines DYN Stock Analysis - Frequently Asked Questions How have DYN shares performed this year? Dyne Therapeutics' stock was trading at $13.30 at the beginning of 2024. Since then, DYN stock has increased by 161.1% and is now trading at $34.73. View the best growth stocks for 2024 here. How were Dyne Therapeutics' earnings last quarter? Dyne Therapeutics, Inc. (NASDAQ:DYN) announced its quarterly earnings results on Monday, August, 12th. The company reported ($0.70) earnings per share for the quarter, beating analysts' consensus estimates of ($0.72) by $0.02. When did Dyne Therapeutics IPO? Dyne Therapeutics (DYN) raised $175 million in an initial public offering on Thursday, September 17th 2020. The company issued 10,300,000 shares at $16.00-$18.00 per share. JPMorgan, Jefferies, Piper Sandler and Stifel served as the underwriters for the IPO. Who are Dyne Therapeutics' major shareholders? Dyne Therapeutics' top institutional investors include Handelsbanken Fonder AB (0.02%), SG Americas Securities LLC (0.02%) and Creative Planning (0.01%). Insiders that own company stock include Venture Fund Xi LP Atlas, Joshua T Brumm, Dirk Kersten, Wildon Farwell, Jonathan Mcneill, Oxana Beskrovnaya, Susanna Gatti High, Richard William Scalzo and John Cox. View institutional ownership trends. How do I buy shares of Dyne Therapeutics? Shares of DYN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Dyne Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Dyne Therapeutics investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Netflix (NFLX) and Palo Alto Networks (PANW). Company Calendar Last Earnings8/12/2024Today10/17/2024Next Earnings (Estimated)11/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:DYN Previous SymbolNYSE:DYN CUSIPN/A CIK1818794 Webwww.dyne-tx.com Phone781-786-8230Fax781-786-8866Employees100Year FoundedN/APrice Target and Rating Average Stock Price Target$51.40 High Stock Price Target$66.00 Low Stock Price Target$42.00 Potential Upside/Downside+48.0%Consensus RatingBuy Rating Score (0-4)3.10 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($3.97) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-235,940,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-68.85% Return on Assets-59.96% Debt Debt-to-Equity RatioN/A Current Ratio26.63 Quick Ratio26.63 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.49 per share Price / Book23.31Miscellaneous Outstanding Shares87,383,000Free Float79,548,000Market Cap$3.03 billion OptionableOptionable Beta1.05 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:DYN) was last updated on 10/17/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredRetire off just one stock ticker?ONE AI Stock is All You Need... There are over 6,000 stocks listed in the market right now. They will NOT m...Behind the Markets | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredAdd $2T of Potential Magic to Your PortfolioRevolutionizing a whole $2T entertainment and licensing industry might sound like the stuff of fairytales. But...Elf Labs | SponsoredEquation for Profits: Volatility = OpportunityFREE Intro to Options Class Online Tonight Prosper Trading Academy | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dyne Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dyne Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.